Second company joins race to produce cardiac laser
This article was originally published in Clinica
Less than two weeks after an FDA advisory panel finally backed a technique known as transmyocardial revascularisation (TMR), a second manufacturer has begun its bid for US approval of its technology for performing the cardiac procedure.
You may also be interested in...
Oncologic Drugs Advisory Committee votes 6-5 that ramucirumab’s benefit/risk profile is favorable in first-line lung cancer, but 13-2 that pivotal trial data do not support approval of Steba’s vascular-targeted, photodynamic therapy for low-risk prostate cancer.
Plaintiff Peter Lurie, former US FDA associate commissioner, expects results of hundreds of clinical trials of approved drugs will become available under ruling against HHS; co-plaintiff sought eteplirsen study data.